Use of albumin in three French university hospitals: is prescription monitoring still useful in 2004?

Purpose Use of albumin (indications and quantities involved) has not been assessed in France since major changes occurred after the publication of Cochrane group meta‐analysis. The objectives of this study were to measure the repartition of albumin indications in three French university hospitals in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmacoepidemiology and drug safety 2007-01, Vol.16 (1), p.79-85
Hauptverfasser: Pradel, Vincent, Tardieu, Sophie, Micallef, Joëlle, Signoret, Anne, Villano, Philippe, Gauthier, Laurence, Vanelle, Patrice, Blin, Olivier
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Purpose Use of albumin (indications and quantities involved) has not been assessed in France since major changes occurred after the publication of Cochrane group meta‐analysis. The objectives of this study were to measure the repartition of albumin indications in three French university hospitals in 2004 and to assess the feasibility and usefulness to implement a prescription‐monitoring program. Methods Exhaustive record of albumin prescription during 2 months in three French university hospitals of Marseille. Inclusion of all patients with a first prescription of albumin between 15 March 2004 and 15 May 2004. Indication, formulation and quantity prescribed were recorded for each prescription. Results One hundred and eighty‐seven patients received a total of 426 prescriptions for a total quantity of 21 094 g of albumin during the study. The first indications were hypoalbuminemia (33% of total quantity), plasmapheresis (30.2%) and ascites or hepatorenal syndrome (13.7%). Fifty per cent of total quantity was used by 14 patients (7.5% of included patients). Conclusions Most of albumin consumption in our study is concentrated on recognized indications or indications without alternative to albumin. The different levels of analysis (number of patient treated, number of prescription and quantities used) must be taken into account when analyzing medications such as albumin. Only a marginal proportion of consumption is expected to be saved with close monitoring of indications. Copyright © 2006 John Wiley & Sons, Ltd.
ISSN:1053-8569
1099-1557
DOI:10.1002/pds.1328